Pluri Yönetim

Yönetim kriter kontrolleri 4/4

Pluri CEO'su Yaky Yanay, Feb2014 tarihinde atandı, in görev süresi 10.75 yıldır. in toplam yıllık tazminatı $ 741.48K olup, şirket hissesi ve opsiyonları dahil olmak üzere 38% maaş ve 62% ikramiyelerden oluşmaktadır. şirketin hisselerinin 4.43% ine doğrudan sahiptir ve bu hisseler $ 1.21M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.9 yıl ve 3 yıldır.

Anahtar bilgiler

Yaky Yanay

İcra Kurulu Başkanı

US$741.5k

Toplam tazminat

CEO maaş yüzdesi	38.0%
CEO görev süresi	10.8yrs
CEO sahipliği	4.4%
Yönetim ortalama görev süresi	2.9yrs
Yönetim Kurulu ortalama görev süresi	3yrs

Son yönetim güncellemeleri

Recent updates

Pluri gains as PROTO project receives €7.5M EU grant

Sep 06

Pluristem Therapeutics renames as Pluri

Jul 25

Pluristem Therapeutics (NASDAQ:PSTI) Has Debt But No Earnings; Should You Worry?

Dec 04

We Think Pluristem Therapeutics (NASDAQ:PSTI) Needs To Drive Business Growth Carefully

Aug 18

What Is The Ownership Structure Like For Pluristem Therapeutics Inc. (NASDAQ:PSTI)?

Mar 15

We're Hopeful That Pluristem Therapeutics (NASDAQ:PSTI) Will Use Its Cash Wisely

Feb 08

CEO Tazminat Analizi

Yaky Yanay'un ücretlendirmesi Pluri'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$22m
Jun 30 2024	US$741k	US$282k	-US$21m
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	n/a	n/a	-US$24m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	US$3m	US$297k	-US$28m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	n/a	n/a	-US$33m
Sep 30 2022	n/a	n/a	-US$36m
Jun 30 2022	US$1m	US$489k	-US$41m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	n/a	n/a	-US$51m
Sep 30 2021	n/a	n/a	-US$53m
Jun 30 2021	US$9m	US$453k	-US$50m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	n/a	n/a	-US$37m
Sep 30 2020	n/a	n/a	-US$31m
Jun 30 2020	US$350k	US$303k	-US$29m
Mar 31 2020	n/a	n/a	-US$29m
Dec 31 2019	n/a	n/a	-US$31m
Sep 30 2019	n/a	n/a	-US$34m
Jun 30 2019	US$887k	US$373k	-US$35m
Mar 31 2019	n/a	n/a	-US$37m
Dec 31 2018	n/a	n/a	-US$28m
Sep 30 2018	n/a	n/a	-US$28m
Jun 30 2018	US$443k	US$393k	-US$26m

Tazminat ve Piyasa: Yaky 'ın toplam tazminatı ($USD 741.48K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 649.63K ).

Tazminat ve Kazançlar: Yaky 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Yaky Yanay (53 yo)

10.8yrs

Görev süresi

US$741,479

Tazminat

Mr. Yaacov Yanay, also known as Yaky, is the Co-Founder of the EyeCue Vision Technologies Ltd. Mr. Yanay has been Chief Executive Officer of Pluri Inc. (formerly Pluristem Therapeutics, Inc.) since June 23...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yaacov Yanay	President	10.8yrs	US$741.48k	4.43% $ 1.2m
Liat Zalts	Chief Financial Officer & Treasurer	less than a year	Veri yok	0.028% $ 7.7k
Lior Raviv	Chief Technology Officer	2.9yrs	Veri yok	Veri yok
Arthur Machlenkin	Chief Scientific Officer	no data	Veri yok	Veri yok
Efrat Livne-Hadass	Chief Wellbeing Officer	no data	Veri yok	Veri yok
Orly Amiran	Chief Quality Officer	no data	Veri yok	Veri yok
Efrat Kaduri	Chief Business Development Officer of Pharma	no data	Veri yok	Veri yok
Nimrod Bar Zvi	Chief Commercial Officer	2.8yrs	Veri yok	Veri yok
John Dvor	EVP North America	no data	Veri yok	Veri yok

2.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim: PLUR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yaacov Yanay	President	9.8yrs	US$741.48k	4.43% $ 1.2m
Doron Birger	Independent Director	3.3yrs	US$66.96k	0.042% $ 11.5k
Zami Aberman	Chairman	19yrs	US$148.17k	2.38% $ 648.0k
James Roosevelt	Member of Advisory Board	less than a year	Veri yok	Veri yok
Yoram Palti	Member of Strategic Advisory Board	2.8yrs	Veri yok	Veri yok
Eilon Tirosh	Member of Strategic Advisory Board	2.8yrs	Veri yok	Veri yok
Richard Kendall	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Maital Shemesh-Rasmussen	Independent Director	3.4yrs	US$63.55k	0.047% $ 12.9k
Prasad Adusumilli	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Rami Levi	Independent Director	3.4yrs	US$60.10k	0.047% $ 12.8k

3.0yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PLUR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3 yıldır).

Pluri Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Pluri Inc. Announces CFO Changes, Effective September 30, 2024

Pluri Inc., Annual General Meeting, Jun 25, 2024

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

High number of new and inexperienced directors

Recent updates

First quarter 2025 earnings released: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024)

New minor risk - Share price stability

Full year 2024 earnings released

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces CFO Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Third quarter 2024 earnings released: US$1.01 loss per share (vs US$1.53 loss in 3Q 2023)

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)

Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 1Q 2023)

Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.77 loss per share (vs US$1.28 loss in FY 2022)

Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

Pluri Inc. announced that it has received $8.469323 million in funding

Pluri Inc. announced that it expects to receive $8.170972 million in funding

Price target decreased to US$7.00

High number of new and inexperienced directors

Pluri Receives Non-Compliance Letter from Nasdaq

Pluri Inc. Announces €7.5 Million Non-Dilutive Grant from the European Union’s Horizon Europe Program to Study PLX-PAD Cells for Osteoarthritis Treatment

Pluri gains as PROTO project receives €7.5M EU grant

Pluristem Therapeutics renames as Pluri

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Pluristem Therapeutics Inc. Announces Board Changes

Price target increased to US$9.75

High number of new directors

Price target increased to US$9.75

High number of new directors

Pluristem Therapeutics Inc. and Tnuva Group Appoint Eyal Rosenthal as Chief Executive Officer of Their New Joint Venture

High number of new directors

Chairman recently bought US$145k worth of stock

Pluristem Therapeutics Inc. Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Price target decreased to US$7.75

Pluristem Therapeutics (NASDAQ:PSTI) Has Debt But No Earnings; Should You Worry?

We Think Pluristem Therapeutics (NASDAQ:PSTI) Needs To Drive Business Growth Carefully

Independent Director Isaac Braun has left the company

Insider recently sold US$1.6m worth of stock

Insider recently sold US$102k worth of stock

Pluristem Reports Positive Topline Phase I Results in Innovative Hematology Program, Which Is First to Study PLX-R18 in humans

What Is The Ownership Structure Like For Pluristem Therapeutics Inc. (NASDAQ:PSTI)?

New 90-day low: US$5.58

Earnings beat expectations

We're Hopeful That Pluristem Therapeutics (NASDAQ:PSTI) Will Use Its Cash Wisely

Pluristem Therapeutics launches $30M registered direct offering

Pluristem Therapeutics Inc. Announces Board Appointments

Have Insiders Been Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares?

Pluristem Therapeutics Inc. Enters Collaboration With Innovare R&D to Expand Its ARDS Associated With COVID-19 Program to Mexico

Pluristem expands COVID-19 program in Mexico

Price target lowered to US$8.50

Pluristem Therapeutics Inc. Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

Pluristem - Moment Of Truth

New 90-day high: US$11.40

Insider recently bought US$194k worth of stock

Market Sentiment Around Loss-Making Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Pluristem Therapeutics Inc. to Present Initial Results from its Phase I HCT Study

Earnings beat expectations

Insider recently bought US$184k worth of stock

Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study

Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects At Malta Conferences Foundation Online Event

Insider recently bought US$97k worth of stock

Full year earnings released - US$1.60 loss per share